Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELLIMIN: Immunosuppression Minimization in Renal Transplantation
NCT02540395Phase 4Completed
- Start
- Mar 2015
- Primary completion
- Oct 2020
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 4, randomised, open-label trial of tacrolimus + Wuzhi capsule in kidney transplant rejection (2 arms). Primary endpoint: assessment of anti-donor T-cell alloresponses using the IFN-γ ELISPOT test at 6 months. Started Mar 2015; status: completed.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02540395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02540395.